# Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct06685276/  
OnCo record `nct06685276` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fruquintinib, sintilimab and tucidinostat (chidamide) in colorectal cancer, run by Dai, Guanghai, now recruiting.

## Summary

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06685276 by Dai, Guanghai, with a registry enrolment figure of 46 participants, started 2024-08-16 and due to reach its primary completion in 2025-12. Interventions recorded: Fruquintinib; Sintilimab; Chidamide. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progress-free Survival(PFS). Colorectal eligibility wording from the registry: "Patients with histologically confirmed unresectable locally advanced, recurrent, or metastatic colorectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06685276
- Phase: 2
- Setting: A Prospective Single-arm Phase Ib/II Study on the Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
- Sponsor: Dai, Guanghai
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06685276: https://clinicaltrials.gov/study/NCT06685276

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06685276.json